Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
|Videos|March 13, 2019
Optimal Treatment of Chemoresistant mCRC
Optimal Treatment of Chemoresistant mCRC
Advertisement
Case: A 60-Year-Old Male With mCRC
Initial presentation
April 2015
- A 60-yearold man was referred to gastroenterology after complaining of general malaise and alternating constipation with bloody diarrhea.
- PE: Showed left-sided lower abdominal pain
- Carcinoembryonic antigen (CEA); 8.1 mg/L
- Colonoscopy revealed a left-sided adenocarcinoma of the colon
- Surgery: left hemicolectomy
- Pathology: well-differentiated adenocarcinoma
- PET/CT: 15/15 lymph nodes tested negative
- Staging: IIIA
- ECOG PS 0
- Patient received adjuvant mFOLFOX4
April 2018
- 24 months later, the patient complained of mild abdominal distension and his stools were pencil-shaped with some presence of blood
- PET/CT scan showed widespread small liver lesions
- CEA; 14.7 mg/L
- Biopsy was CK2-positive
- Molecular testing; allRAS&BRAFWT
- ECOG PS 1
- Patient began treatment with FOLFIRI + bevacizumab
February 2019
- PET/CT scan showed evidence of new liver lesions and a 2-cm mass in the right lung
- CEA; 31.7 mg/L
- Patient started on regorafenib 80 mg/day
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
5